Fitch Affirms Grupo Ferroviario Mexicano at 'BBB+'; Ferromex at 'AAA(mex)'; Outlook Stable
Fitch Affirms SBP DPR Finance Co's Ratings at 'A+'; Outlook Stable
EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
CST Brands, Inc. Commences Registered Exchange Offer for 5.00% Senior Notes Due 2023
Key operational trends suggest the Big Three incumbents' economic moats are intact.